SimpleScreen CRC is a US-approved blood test for colorectal-cancer screening in average-risk adults aged 45 and over. A positive result leads to colonoscopy; the blood test does not complete the diagnostic pathway on its own.
Its introduction adds a screening option, but it does not make blood, stool and visual examinations equivalent. Detecting an existing cancer, finding a precancerous lesion and helping a person complete screening are different questions.
What the approval covers
The FDA’s original safety and effectiveness assessment describes a test looking for molecular signals associated with colorectal cancer in circulating cell-free DNA. The indication excludes using it as a substitute for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Those boundaries matter. A screening test for a defined average-risk population cannot be assumed suitable for every person with symptoms, a previous finding or a higher-risk history. The label and clinical assessment determine the relevant pathway.
Abbott’s September launch announcement places the Freenome-developed test alongside its stool-based screening offering. That is a commercial launch account, rather than a head-to-head trial proving one option is best for every patient.
Cancer detection and precursor detection differ
In the FDA’s primary evaluable dataset, 27,010 participants had confirmed clinical findings and a valid test result. The unadjusted results included the following:
| Reference finding | Detected by the blood test | What that proportion describes |
|---|---|---|
| Colorectal cancer | 57 of 72, or 79.2% | Sensitivity for cancers present in this evaluable study population. |
| Advanced precancerous lesion | 321 of 2,567, or 12.5% | Sensitivity for these precursor findings, rather than for cancer itself. |
The report separately gives age-and-sex census-adjusted estimates, including 81.1% cancer sensitivity and 13.7% sensitivity for advanced precancerous lesions. Those estimates use a different calculation from the raw counts. They should not be mixed into one supposedly exact detection rate.
The distinction also explains why an attractive cancer-detection percentage does not establish the same ability to find changes before cancer develops. Nor does a negative result guarantee that no important finding is present.
Why guidelines still distinguish the options
The American Cancer Society’s 2026 guideline summary prefers stool-based tests and visual examinations over blood-based tests at this time. It identifies lower detection of precancerous growths and early-stage cancers as important reasons.
The Society also includes blood-based screening among recommended options and emphasises participation. These positions address different issues: an option may help reach someone who would otherwise remain unscreened while still having limitations compared with preferred approaches.
For every non-colonoscopy screening test, the guideline makes timely colonoscopy after a positive finding part of the screening process. A convenient first sample therefore needs a workable follow-up route, including access to the next appointment.
This is not a ranking built from unrelated trial percentages. Different tests can have different study populations, versions and reference definitions. A comparison needs those details as well as the practical demands of completing the pathway.
Keep the version and the outcome straight
The original approval assessment and subsequent announcements should not be treated as one unchanging dataset. The August FDA supplement concerns manufacturing processes for critical reagents. Its existence does not establish approval of every proposed future assay improvement.
The validation also does not directly demonstrate a reduction in colorectal-cancer deaths. Our multi-cancer blood-test explainer examines why detection and mortality require different evidence; that distinction remains relevant to a single-cancer test.
SimpleScreen CRC’s useful role is consequently a defined screening option within a wider service. The eligible population, precursor-detection limits, actual test version and colonoscopy follow-up are all part of understanding that role.